Clinical trial
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive…
NCT00102388 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00102388 |
|---|---|
| Title | Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes |
| Official title | Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | vildagliptin, Gliclazide |
| Enrollment | 1,092 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2008 |
| First posted | Jan 31, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: